A5376
乙酰水杨酸
≥99.0%
别名:
2-乙酰氧基苯甲酸, O-乙酰水杨酸, ASA, 阿司匹林
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
线性分子式:
2-(CH3CO2)C6H4CO2H
化学文摘社编号:
分子量:
180.16
UNSPSC Code:
12352106
NACRES:
NA.21
PubChem Substance ID:
EC Number:
200-064-1
Beilstein/REAXYS Number:
779271
MDL number:
biological source
synthetic
Quality Level
assay
≥99.0%
form
powder
color
white
pKa (25 °C)
3.5
mp
134-136 °C (lit.)
solubility
H2O: 10 mg/mL at 37 °C(lit.), H2O: 3 mg/mL at 25 °C(lit.), ethanol: 50 mg/mL, aqueous base: decomposes
ε (extinction coefficient)
190 at 298 nm in aqueous base at 1 mM, 409 at 231 nm in aqueous base at 1 mM, 466 at 230 nm in aqueous acid at 1 mM, 68 at 278 nm in aqueous acid at 1 mM
SMILES string
CC(=O)Oc1ccccc1C(O)=O
InChI
1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
InChI key
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
Gene Information
human ... ITGA2B(3674), ITGB3(3690), PTGS1(5742), PTGS2(5743)
General description
乙酰水杨酸是一种有机化合物，通常被称为阿司匹林。它通过阻止体内引发疼痛、肿胀和发热的化合物的产生来起作用。乙酰水杨酸还在预防动脉中形成血凝块方面发挥重要作用。在研究中，乙酰水杨酸被研究其在氧化应激中的作用，并在癌症研究作为生物标志物。
Biochem/physiol Actions
通过抑制环氧化酶(前列腺素H合酶)，对COX-1亚型具有更高的选择性，阻止前列腺素的产生。抗血栓作用是由于COX-1在血小板中的抑制作用，阻止血栓形成和血小板聚集。 对结直肠及其他实体肿瘤有化学预防作用。
Still not finding the right product?
Explore all of our products under 乙酰水杨酸
signalword
Warning
hcodes
存储类别
11 - Combustible Solids
flash_point_f
482.0 °F
flash_point_c
250 °C
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 3
Connie N Hess et al.
Journal of the American College of Cardiology, 66(7), 777-787 (2015-08-14)
Bleeding limits anticoagulant treatment in patients with acute coronary syndromes (ACS). We investigated whether background concomitant antiplatelet therapy influences the effects of apixaban after ACS. This study examined high-risk ACS patients who were treated with aspirin or aspirin plus clopidogrel
Niels Hulsman et al.
Journal of medicinal chemistry, 50(10), 2424-2431 (2007-04-20)
Hybrid drug 1 (NO-ASA) continues to attract intense research from chemists and biologists alike. It consists of ASA and a -ONO2 group connected through a spacer and is in preclinical development as an antitumor drug. We report that, contrary to
Christina Perneby et al.
Thrombosis and haemostasis, 95(4), 652-658 (2006-04-08)
Aspirin is widely used, but dosages in different clinical situations and the possible importance of "aspirin resistance" are debated. We performed an open cross-over study comparing no treatment (baseline) with three aspirin dosage regimens--37.5 mg/day for 10 days, 320 mg/day
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| A5376-250G | 04061833375815 |
| A5376-100G | 04061835542253 |
| A5376-1KG | 04061833375808 |
| A5376-500G | 04061835542260 |